Borghi C, et al. - Whether use of sulfhydryl angiotensin-converting enzyme (ACE)-inhibitors (ACEIs), such as zofenopril or captopril plus xanthine oxidase inhibitors (XOIs) would result in enhanced antioxidant effects and improved survival in post-acute myocardial infarction (AMI) patients was assessed in a randomly stratified sample of post-AMI patients in the four randomized prospective SMILE (Survival of Myocardial Infarction Long-term Evaluation) studies. Researchers compared the 1-year combined risk of major cardiovascular events (MACE, death or hospitalization for cardiovascular causes) between four groups of patients treated with XOIs (79 with zofenopril, 86 with placebo, lisinopril or ramipril) and those who were not (192 zofenopril, 168 placebo or other ACEIs). They found that a combination of a urate lowering drug with antioxidant activity and an ACEI provided an improved survival free from MACE; zofenopril offered the best effects in this retrospective analysis.